The search for nucleoside/nucleotide analog inhibitors of dengue virus

Yen Liang Chen, Fumiaki Yokokawa, Pei-Yong Shi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Abstract Nucleoside analogs represent the largest class of antiviral agents and have been actively pursued for potential therapy of dengue virus (DENV) infection. Early success in the treatment of human immunodeficiency virus (HIV) infection and the recent approval of sofosbuvir for chronic hepatitis C have provided proof of concept for this class of compounds in clinics. Here we review (i) nucleoside analogs with known anti-DENV activity; (ii) challenges of the nucleoside antiviral approach for dengue; and (iii) potential strategies to overcome these challenges. This article forms part of a symposium in Antiviral Research on flavivirus drug discovery.

Original languageEnglish (US)
Article number3670
Pages (from-to)12-19
Number of pages8
JournalAntiviral Research
Volume122
DOIs
StatePublished - Aug 10 2015
Externally publishedYes

Fingerprint

Dengue Virus
Nucleosides
Antiviral Agents
Nucleotides
Virus Diseases
Flavivirus
Dengue
Chronic Hepatitis C
Drug Discovery
HIV
Research
Therapeutics

Keywords

  • Antiviral therapy
  • Dengue virus
  • Monophosphate prodrug
  • Nucleoside analogs

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

The search for nucleoside/nucleotide analog inhibitors of dengue virus. / Chen, Yen Liang; Yokokawa, Fumiaki; Shi, Pei-Yong.

In: Antiviral Research, Vol. 122, 3670, 10.08.2015, p. 12-19.

Research output: Contribution to journalArticle

Chen, Yen Liang ; Yokokawa, Fumiaki ; Shi, Pei-Yong. / The search for nucleoside/nucleotide analog inhibitors of dengue virus. In: Antiviral Research. 2015 ; Vol. 122. pp. 12-19.
@article{d28ea681357f4aae99e5438c2642ef4e,
title = "The search for nucleoside/nucleotide analog inhibitors of dengue virus",
abstract = "Abstract Nucleoside analogs represent the largest class of antiviral agents and have been actively pursued for potential therapy of dengue virus (DENV) infection. Early success in the treatment of human immunodeficiency virus (HIV) infection and the recent approval of sofosbuvir for chronic hepatitis C have provided proof of concept for this class of compounds in clinics. Here we review (i) nucleoside analogs with known anti-DENV activity; (ii) challenges of the nucleoside antiviral approach for dengue; and (iii) potential strategies to overcome these challenges. This article forms part of a symposium in Antiviral Research on flavivirus drug discovery.",
keywords = "Antiviral therapy, Dengue virus, Monophosphate prodrug, Nucleoside analogs",
author = "Chen, {Yen Liang} and Fumiaki Yokokawa and Pei-Yong Shi",
year = "2015",
month = "8",
day = "10",
doi = "10.1016/j.antiviral.2015.07.010",
language = "English (US)",
volume = "122",
pages = "12--19",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - The search for nucleoside/nucleotide analog inhibitors of dengue virus

AU - Chen, Yen Liang

AU - Yokokawa, Fumiaki

AU - Shi, Pei-Yong

PY - 2015/8/10

Y1 - 2015/8/10

N2 - Abstract Nucleoside analogs represent the largest class of antiviral agents and have been actively pursued for potential therapy of dengue virus (DENV) infection. Early success in the treatment of human immunodeficiency virus (HIV) infection and the recent approval of sofosbuvir for chronic hepatitis C have provided proof of concept for this class of compounds in clinics. Here we review (i) nucleoside analogs with known anti-DENV activity; (ii) challenges of the nucleoside antiviral approach for dengue; and (iii) potential strategies to overcome these challenges. This article forms part of a symposium in Antiviral Research on flavivirus drug discovery.

AB - Abstract Nucleoside analogs represent the largest class of antiviral agents and have been actively pursued for potential therapy of dengue virus (DENV) infection. Early success in the treatment of human immunodeficiency virus (HIV) infection and the recent approval of sofosbuvir for chronic hepatitis C have provided proof of concept for this class of compounds in clinics. Here we review (i) nucleoside analogs with known anti-DENV activity; (ii) challenges of the nucleoside antiviral approach for dengue; and (iii) potential strategies to overcome these challenges. This article forms part of a symposium in Antiviral Research on flavivirus drug discovery.

KW - Antiviral therapy

KW - Dengue virus

KW - Monophosphate prodrug

KW - Nucleoside analogs

UR - http://www.scopus.com/inward/record.url?scp=84938847891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938847891&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2015.07.010

DO - 10.1016/j.antiviral.2015.07.010

M3 - Article

VL - 122

SP - 12

EP - 19

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

M1 - 3670

ER -